BioPharma Reporter
DECEMBER 11, 2023
Dr. Michael OâNeal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
Bio Pharma Dive
DECEMBER 11, 2023
AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 11, 2023
Trends in sustainability and quality assurance were key themes discussed at the recent CPHI Europe 2023 meeting, although the data reveals a lack of implementation of sustainable solutions.
Bio Pharma Dive
DECEMBER 11, 2023
Editas had the tall task Monday of convincing ASH attendees its gene therapy for sickle cell disease could improve on Casgevy and Lyfgenia.
Pharmaceutical Technology
DECEMBER 11, 2023
The FDA has approved Vertex/CRISPR’s Casgevy and bluebird bio’s Lyfgenia gene therapies for the red blood cell disorder.
Bio Pharma Dive
DECEMBER 11, 2023
A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
DECEMBER 11, 2023
Research from Everest Group shows how life sciences leaders are investing in process mining to speed time-to-market, improve regulatory compliance and drive innovation.
Pharmaceutical Technology
DECEMBER 11, 2023
We analyse dropout data and speak to DCT expert, Ellen Weiss, to explore the power of mobile visits in improving patient engagement and retention rates.
XTalks
DECEMBER 11, 2023
Medical device companies continue to maintain a crucial role in enhancing patient care and diagnostic precision in 2023. Through the utilization of their state-of-the-art technology and substantial investments in research and development (R&D), these med tech/medical device companies persist in driving industry innovation beyond the pandemic, thereby laying the foundation for a more streamlined approach against diseases in the future.
Pharmaceutical Technology
DECEMBER 11, 2023
The funding will advance Hoba’s lead candidate HB-086 to Phase I clinical trial for chemotherapy induced neuropathic pain.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
DECEMBER 11, 2023
New data highlights the inequalities in emergency hospital rates and vaccinations - News - PharmaTimes
Pharmaceutical Technology
DECEMBER 11, 2023
Ferring Pharmaceuticals has signed an R&D partnership agreement with PharmaBiome to develop microbiome-based therapies in gastroenterology.
BioSpace
DECEMBER 11, 2023
Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.
Pharmaceutical Technology
DECEMBER 11, 2023
A study shared at ASH saw lupus and sclerosis patients make marked recoveries through CAR-T therapy initally targeted at blood cancers.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharma Times
DECEMBER 11, 2023
Around 2,100 GP surgeries had enrolled into the digital service by the end of November - News - PharmaTimes
Pharmaceutical Technology
DECEMBER 11, 2023
The US FDA has granted approval for Astellas Pharma’s Cresemba to treat children with invasive aspergillosis and invasive mucormycosis.
Outsourcing Pharma
DECEMBER 11, 2023
Science and technology giant, Merck, has launched its first software-as-a-service (SaaS) platform that it says bridges the gap between virtual molecule design and real-world manufacturability.
Pharmaceutical Technology
DECEMBER 11, 2023
Novartis is seeking approval for Kisqali as a treatment of early breast cancer, with an FDA application planned by the end of 2023.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
DECEMBER 11, 2023
Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.
Pharmaceutical Technology
DECEMBER 11, 2023
Nona Biosciences has entered a partnership deal with biopharmaceutical company Evive Biotech to discover antibodies.
BioSpace
DECEMBER 11, 2023
Following the regulator’s administrative complaint and threat of a lawsuit in federal court, Sanofi has decided to terminate its licensing deal with Maze Therapeutics to avoid a long litigation process.
Outsourcing Pharma
DECEMBER 11, 2023
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
DECEMBER 11, 2023
With the acquisition, AstraZeneca will gain access to Icosavax’s investigational combination vaccine IVX-A12, which is being developed for respiratory syncytial virus and human metapneumovirus in older adults.
Fierce Pharma
DECEMBER 11, 2023
After many years of tracking the pharmaceutical industry’s pricing tactics, the Institute for Clinical and Economic Review (ICER) is once again placing a spotlight on the price increases that end u | The Institute for Clinical and Economic Review (ICER)’s fifth annual report on unsupported price increases (UPI) puts Humira in the top spot of offenders.
BioSpace
DECEMBER 11, 2023
The companies have received all required regulatory approvals to complete the deal, the largest for the sector in the past three years and the biggest for the hot antibody-drug conjugate market.
Outsourcing Pharma
DECEMBER 11, 2023
Last-line multiple myeloma patients, who have exhauster other treatment options have been responding to oral drug inobrodib in combination with pomalidomide and dexamethasone (pom and dex).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
DECEMBER 11, 2023
The trial demonstrated that C3G glomerulopathy patients treated with the oral factor B inhibitor saw a significant reduction in protein in their urine. The results come days after iptacopan won the FDA’s green light for a rare blood disease.
pharmaphorum
DECEMBER 11, 2023
Predictive genetic testing offers the greatest promise and ethical challenge of our time Mike.
Fierce Pharma
DECEMBER 11, 2023
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy aliu Mon, 12/11/2023 - 14:51
Pharmaceutical Commerce
DECEMBER 11, 2023
Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
98 
Let's personalize your content